IntelGenx Acquires Full Ownership and Exclusive Rights to MS Induced Pain Product
SAINT LAURENT, QUEBEC–(Marketwire – 11/29/10) – IntelGenx Corp. (TSX-V: IGX – News )(OTC.BB: IGXT – News ) (“IntelGenx”) today announced that it has acquired exclusive rights to, and ownership of, INT0010, an improved formulation of THC (dronabinol) for the symptomatic management of Multiple Sclerosis (MS) induced neuropathic pain and chemotherapy induced nausea. These markets are multi-billion …
Read more on Marketwire via Yahoo! Finance
